The Barriers Limiting Radiopharmaceutical Access
September 21, 2026
From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology
5 min read
False
Advertisement
September
Long-Term Data Boost MCO-010
September 21, 2026
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
2 min read
Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?
September 18, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale
1 min read
The Power of Policy
September 17, 2026
What one policy change would accelerate progress in drug development and manufacturing? We asked the 2026 Power List.
8 min read
The GLP-1 Capacity Squeeze
September 16, 2026
As demand for GLP-1 medicines grows, injectable manufacturers must increase output without compromising quality or squeezing supply for other therapies
4 min read
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
September 16, 2026
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
2 min read
Novartis and BMS Pause Autoimmune CAR T Trials Over Safety Concerns
September 16, 2026
Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies
2 min read
AI-Designed Binder Improves CAR T Cell Activity in Mice
September 15, 2026
Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control
2 min read
Musings from The Power List: Dajun Yang
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
Biomarker Could Predict Response to Low-Dose CAR T Cell Therapy
September 14, 2026
CD27-negative, CD39-negative CAR T cells were associated with treatment response when limited cell numbers were administered
3 min read
Browse by Topics
Interviews
Cell & Gene
Bioprocessing
Drug Delivery
Drug Discovery
Development & Clinical
Formulation
Facilities & Equipment
Outsourcing
Packaging
Regulation & Standards
Small Molecules
Supply Chain
Industry News
Research News
Sitting Down With
Innovation Awards
Business & Trends
Technology & Manufacturing
Biopharma
Future of Pharma
Latest
Blogs
Power List